Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Clinical trials of pharmacotherapy to prevent progression of cognitive decline in those with mild cognitive impairment (MCI) have been disappointing; neither cholinesterase inhibitors (donepezil, rivastigmine, galantamine), vitamin E, nor COX-2 inhibitors has demonstrated any clinically meaningful benefit in placebo-controlled MCI trials.

Clinical Briefs By Louis Kuritzky, MD